Cleveland Clinic London Hospital has launched the first phase of its central intravenous additive service unit for non-hazardous sterile compounds.
Once fully operational, it will be the first U.K. hospital to provide 24/7 production of non-hazardous sterile compounds through a central intravenous additive service, according to a LinkedIn post by Lindsey Amerine, PharmD, chief pharmacy officer of Cleveland Clinic.
Calling this project "a huge milestone," Dr. Amerine expressed pride in being part of the team driving the initiative.